#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
The endocannabinoid system relies on two key enzymes, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), to regulate levels of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol (2-AG) respectively. Understanding this enzymatic degradation pathway is clinically relevant because inhibiting these enzymes represents a potential therapeutic strategy to increase endogenous cannabinoid signaling without exogenous cannabis use, and because variations in enzyme expression may influence individual responses to both cannabis and future enzyme-inhibitor medications. Currently, FAAH and MAGL inhibitors are in development and preclinical/clinical testing for conditions including pain, anxiety, and inflammation, offering a complementary approach to direct cannabinoid receptor agonism. For clinicians, awareness of this system helps contextualize why some patients may respond differently to cannabis products and informs discussion of future pharmacological options that may provide more precise endocannabinoid modulation than whole-plant cannabis. Clinicians should recognize that the endocannabinoid system is a legitimate pharmaceutical target with ongoing research, which may lead to standardized medications with predictable dosing and effects compared to current cannabis products.
“The endocannabinoid system is genuinely fascinating from a physiological standpoint, and understanding how FAAH and MAGL regulate our natural cannabinoids gives us a framework for thinking about cannabis therapeutics, but we need to be honest that translating this basic biology into reliable clinical applications remains an active area of investigation rather than settled science.”
🧠 Understanding the endocannabinoid system’s enzymatic regulation—particularly the roles of FAAH and MAGL in metabolizing endogenous cannabinoids anandamide and 2-AG—provides mechanistic insight into how exogenous cannabis and targeted pharmacotherapy might modulate pain, mood, and inflammatory responses in clinical populations. However, the translation from basic enzyme biology to therapeutic benefit remains incomplete; individual genetic variations in these enzymes, complex downstream signaling interactions, and the challenge of achieving site-specific effects without systemic side effects all complicate clinical application. Current evidence supporting cannabis for specific conditions such as chemotherapy-induced nausea or certain seizure disorders is stronger than evidence for broader chronic pain or psychiatric indications, and the high variability in product composition, dosing, and cannabinoid ratios available to patients limits the ability to apply mechanistic knowledge consistently. Clinicians should recognize that patient interest in cannabis
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
